The Call of Commerce: Former Academics Cite Advantages in Industry

The excitement of turning theory into therapeutics...The opportunity to focus on research, without the distractions of committee work...The prospect of advancing one's career without navigating the tenure process...The chance to collaborate, rather than carve an individual niche...The potential for greater remuneration--if the science proves marketable... A host of reasons prompts scientists to ponder switching from academia to industry--whether as start-up employee, biotech entrepreneur, or B

Written byPaul Smaglik
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

A host of reasons prompts scientists to ponder switching from academia to industry--whether as start-up employee, biotech entrepreneur, or Big Pharma scientific director. These reasons tend to be unique to each person's situation. But two underlying forces may be at the roots of these personal choices, which both surveys and stories indicate more scientists are making.

Rolf F. Lehming, director of the integrated studies program at the National Science Foundation's division of science resources studies, thinks a "push and pull" phenomenon has driven the trend. The "push," posits Lehming, comes from academic hiring-- or lack thereof. Academic hiring has slowed considerably since a boom beginning in the 1960s. "In the early '70s, academia employed 55 percent of all doctoral scientists and engineers in the [United States]," Lehming says. "That's now down to about 46 percent." The rate of hiring new, full-time professors in universities flattened in the '90s--with only enough ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies